It's the first drug for treatment of the disease in a country with a rapidly aging population.
Developed by Japanese drugmaker Eisai Co. and U.S. biotechnology firm Biogen Inc., the drug's approval in Japan comes two months after it was endorsed by the U.S. Food and Drug Administration.
Prime Minister Fumio Kishida, who announced Japan's approval of Leqembi on Monday, called it “a breakthrough” and said that the “treatment of dementia has now entered a new era.” According to the health ministry, Japan's number of dementia patients who are 65 years of age or older will rise to 7 million in 2025, from the current 6 million.
Eisai said it will conduct a post-marketing special use survey in all patients administered the drug until enough data is collected from unspecified number of patients under Japanese health ministry procedures.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Japan, with 6 million Alzheimer's patients, approves first drug to treat conditionIt's the first drug for treatment of the disease in a country with a rapidly aging population.
Leer más »
Japan, with 6 million Alzheimer's patients, approves first drug to treat conditionIt's the first drug for treatment of the disease in a country with a rapidly aging population.
Leer más »
Japan, with 6 million Alzheimer's patients, approves first drug to treat conditionIt's the first drug for treatment of the disease in a country with a rapidly aging population.
Leer más »
After US approval, Japan OKs Leqembi, its first Alzheimer's drug, developed by Eisai and BiogenJapan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
Leer más »
After US approval, Japan approves Leqembi, its first Alzheimer's drugJapan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was jointly developed by Japanese and U.S. pharmaceutical companies.
Leer más »
After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and BiogenJapan’s health ministry has approved Leqembi, a drug for Alzheimer’s decease that was...
Leer más »